We thank Drs. Chugh and Chugh for their interest in our work (1) and for their comments. We agree that access failure remains a limitation of transradial intervention (TRI) 
have smaller radial arteries, and as the authors suggest, arterial-sheath size mismatch might cause RAS. Our protocol did not recommend sizes for sheaths/catheters, nor did we routinely collect this information, limiting our ability to explore this hypothesis in our female population. Data suggest that most U.S. operators use 5-F or 6-F sheaths for diagnostic catheterization and 6-F sheaths for coronary intervention (2). More slender equipment might reduce RAS in women. However, our access site crossover rate was consistent with that from the RIVAL (Radial versus Femoral Access for Coronary Intervention) trial, which studied a predominantly male population (3), suggesting that factors 
Safety and Feasibility of Transradial Catheterization in Breast Cancer Survivors A 2-Center International Experience
The technical feasibility of transradial access (TRA) in breast cancer survivors is usually not a concern; even so, the perceived fear of lymphedema, both on the part of the survivor and medical staff, is the limiting factor. Cardiac catheterization and percutaneous coronary intervention using TRA is associated with lower rates of vascular and bleeding complications (1-3).
However, relegating breast cancer survivors to only femoral access denies these benefits of TRA to a large group of predominantly female patients. Therefore, the aim of this report is to describe the safety and feasibility of TRA in patients with prior ipsilateral breast cancer undergoing cardiac catheterization.
We retrospectively analyzed all breast cancer patients who underwent coronary catheterizations over Letters to the Editor A P R I L 2 0 , 2 0 1 5 : 6 3 8 -4 2
